| Literature DB >> 11671842 |
Yongfeng Wang1, Malcolm F. G. Stevens, Donald DiBenedetto, Dinesh Gala, Donald Hou, Max Kugelman, William Leong, Janet L. Mas, Doris P. Schumacher, Bruce P. Shutts, Lyman Smith, Zheng-Yun J. Zhan, William T. Thomson.
Abstract
Three new pathways to the antitumor drug temozolomide (4) have been explored via intermediates 3, 6, and 7. The key intermediate 5-amino-1-(N-methylcarbamoyl)imidazole-4-carboxamide (6) has been successfully converted to 4 in 45% yield by employing sodium nitrite in aqueous tartaric acid at 0-5 degrees C. Compound 6 is prepared from nitrophenyl carbamate 14a and methylamine or directly from 5-aminoimidazole-4-carboxamide (13) and either methyl isocyanate or N-methylcarbamoyl chloride. Temozolomide (4) is also prepared from 8-cyano-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (7) by hydrolysis to the hydrochloride salt of 4 in 10 M hydrochloric acid. Compound 7is prepared from either 5-diazoimidazole-4-carbonitrile (28) and methyl isocyanate or by diazotization of 5-amino-1-(N-methylcarbamoyl)imidazole-4-carbonitrile (25). Attempts to cyclize 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (3) with phosgene or phosgene equivalents were unsuccessful: only 2-azahypoxanthine (11) was isolated.Entities:
Year: 1997 PMID: 11671842 DOI: 10.1021/jo970802l
Source DB: PubMed Journal: J Org Chem ISSN: 0022-3263 Impact factor: 4.354